Last $0.05 USD
Change Today -0.0214 / -31.47%
Volume 27.2M
PSID On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1690 South Congress Avenue

Suite 201

Delray Beach, FL 33445

United States

Phone: 561-805-8000

Fax: 561-805-8001

PositiveID Corporation, through its wholly-owned subsidiary, MicroFluidic Systems, develops molecular diagnostic systems for bio-threat detection and rapid medical testing. The company also develops fully automated pathogen detection systems and assays to detect a range of biological threats. The company’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) system is an airborne bio-threat detection system developed for the homeland defense industry to detect biological weapons of mass destruction. The company is also developing the Firefly Dx, an automated pathogen detection system for rapid diagnostics, both for clinical and point of need applications. The company is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays to detect biological threats at high-value locations, as well as analyze samples in a medical environment. The company engages in the development and production of automated instruments for detecting and processing biological samples. The company has a portfolio of intellectual property related to sample preparation and rapid medical testing applications. The company’s M-BAND technology, developed under contract with the U.S. DHS Science & Technology directorate, is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. M-BAND continuously and autonomously analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for approximately 30 days. The company’s Firefly Dx system is designed to deliver molecular diagnostic results from a sample in approximately 30 minutes, which would enable accurate diagnostics leading to rapid and effective treatment than what is available with existing systems. Firefly is being developed further for a range of biological detection situations, including radiation-induced cell damage within the human body and strains of influenza. The handheld Firefly system has already demonstrated the ability to detect and identify other common pathogens and diseases, such as E. coli, methicillin-resistant staphylococcus aureus, and human papilloma virus. iglucose The iglucose system uses machine to machine technology to automatically communicate a diabetic’s glucose readings to the iglucose online database. iglucose is intended to provide next generation, real-time data to improve diabetes management and help ensure patient compliance, data accuracy, and insurance reimbursement. The company obtained Federal Drug Administration of the United States Government clearance. In 2013, the company entered into an agreement with Smart Glucose Meter Corp; Easy Check Medical Diagnostics, LLC; and Easy-Check Medical Diagnostic Technologies Ltd., an Israeli company, pursuant to which the company licensed its iglucose technology to Smart Glucose Meter Corp. GlucoChip The GlucoChip, a product that combines a glucose-sensing microtransponder based on the company’s patent number 7,125,382 entitled ‘Embedded Bio-Sensor System’ with an in-vivo glucose sensor. The company’s patent covers a bio-sensor system that utilizes radio frequency identification (RFID) technology, combining wireless communication with an implantable passively-powered on-chip transponder. The company has partnered with Receptors LLC, a technology company whose AFFINITY by DESIGN chemistry platform could be applied to the development of selective binding products, to develop an in-vivo glucose sensor to detect glucose levels in the human body. The glucose sensor is intended to be coupled with the company’s microchip to read blood glucose levels through an external scanner. The GlucoChip development is on hold while the company seeks an industry partner, licensor, or strategic buyer to continue the project. Breath Glucose Test The breath glucose test, under development, is a non-invasive glucose detection system that measures acetone levels in a patient’s exhaled breath. The breath glucose test detection system combines a proprietary chemical mixture of sodium nitroprusside with breath exhalate, which is intended to create a new molecular compound that could be

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSID:US $0.05 USD -0.0214

PSID Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALR Technologies Inc $0.04 USD +0.0031
Medtronic Inc $63.84 USD +1.85
Microsoft Corp $44.08 USD +0.45
View Industry Companies
 

Industry Analysis

PSID

Industry Average

Valuation PSID Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POSITIVEID CORP, please visit www.positiveidcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.